{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Haemophilia+A&page=5",
    "query": {
      "condition": "Severe Haemophilia A",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 122,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Haemophilia+A&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Haemophilia+A&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T00:34:32.324Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03588299",
      "title": "Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a \"Shuttle\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAY2599023 (DTX201)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2018-11-07",
      "completion_date": "2026-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03588299"
    },
    {
      "nct_id": "NCT05147662",
      "title": "A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment of Bleeding",
        "Prophylaxis of Bleeding",
        "Hemophilia A",
        "Children"
      ],
      "interventions": [
        {
          "name": "Damoctocog alfa pegol (Jivi, BAY94-9027)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "7 Years to 11 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2022-03-23",
      "completion_date": "2025-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05147662"
    },
    {
      "nct_id": "NCT02093065",
      "title": "Platelet Function in Patients With Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "2 Years to 18 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2015-03",
      "completion_date": "2020-02-01",
      "has_results": false,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02093065"
    },
    {
      "nct_id": "NCT01620801",
      "title": "Hemophilia B Gene Therapy With AAV8 Vector",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "AAV8-hFIX19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2012-10",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01620801"
    },
    {
      "nct_id": "NCT00092976",
      "title": "Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "ReFacto",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "6 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2003-02",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-12-28",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00092976"
    },
    {
      "nct_id": "NCT01619046",
      "title": "Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "GreenGene™ F and an approved recombinant Factor VIII product",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GreenGene™ F",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Green Cross Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2013-03",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2014-07-03",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619046"
    },
    {
      "nct_id": "NCT04303559",
      "title": "The Hemophilia Inhibitor Prevention Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A Without Inhibitor"
      ],
      "interventions": [
        {
          "name": "Eloctate Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab Injection [Hemlibra]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "4 Years",
        "sex": "MALE",
        "summary": "4 Months to 4 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2021-10-11",
      "completion_date": "2022-06-16",
      "has_results": true,
      "last_update_posted_date": "2023-04-11",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04303559"
    },
    {
      "nct_id": "NCT01580293",
      "title": "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAY94-9027",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 145,
      "start_date": "2012-04-23",
      "completion_date": "2019-11-21",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Sacramento, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01580293"
    },
    {
      "nct_id": "NCT01775618",
      "title": "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAY94-9027",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "Up to 12 Years · Male only"
      },
      "enrollment_count": 73,
      "start_date": "2013-05-29",
      "completion_date": "2020-02-19",
      "has_results": false,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01775618"
    },
    {
      "nct_id": "NCT01405742",
      "title": "Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rF.VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2012-07",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-10-14T00:34:32.324Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01405742"
    }
  ]
}